Craig Jordan

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint The potential of targeting malignant stem cells as a treatment for leukemia
    Craig T Jordan
    University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA
    Future Oncol 1:205-7. 2005
  2. ncbi request reprint Cancer stem cells
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    N Engl J Med 355:1253-61. 2006
  3. pmc Can we finally target the leukemic stem cells?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 21:615-20. 2008
  4. ncbi request reprint Cancer stem cell biology: from leukemia to solid tumors
    Craig T Jordan
    Division of Hematology Oncology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 703, Rochester, New York 14642, USA
    Curr Opin Cell Biol 16:708-12. 2004
  5. pmc Cancer stem cells: controversial or just misunderstood?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cell Stem Cell 4:203-5. 2009
  6. ncbi request reprint Mechanisms controlling pathogenesis and survival of leukemic stem cells
    Craig T Jordan
    Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
    Oncogene 23:7178-87. 2004
  7. ncbi request reprint Searching for leukemia stem cells--not yet the end of the road?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer Cell 10:253-4. 2006
  8. pmc The leukemic stem cell
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 20:13-8. 2007
  9. doi request reprint Targeting myeloid leukemia stem cells
    Craig T Jordan
    Departments of Medicine and Biomedical Genetics and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Sci Transl Med 2:31ps21. 2010
  10. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009

Research Grants

  1. Cellular and Molecular Studies of Leukemic Stem Cellss
    Craig Jordan; Fiscal Year: 2006
  2. Selective in vivo Ablation of Leukemia Stem Cells
    Craig Jordan; Fiscal Year: 2007
  3. Amnis ImageStream Flow Cytometer
    Craig Jordan; Fiscal Year: 2007
  4. Selective in vivo Ablation of Leukemia Stem Cells
    Craig Jordan; Fiscal Year: 2009

Collaborators

Detail Information

Publications36

  1. ncbi request reprint The potential of targeting malignant stem cells as a treatment for leukemia
    Craig T Jordan
    University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA
    Future Oncol 1:205-7. 2005
    ..This perspective article summarizes recent findings in the leukemia stem cell field and discusses new directions for therapy...
  2. ncbi request reprint Cancer stem cells
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    N Engl J Med 355:1253-61. 2006
  3. pmc Can we finally target the leukemic stem cells?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 21:615-20. 2008
    ..Parameters are suggested here to help identify and quantitate leukemic stem cells in the clinical context...
  4. ncbi request reprint Cancer stem cell biology: from leukemia to solid tumors
    Craig T Jordan
    Division of Hematology Oncology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 703, Rochester, New York 14642, USA
    Curr Opin Cell Biol 16:708-12. 2004
    ..Hence, a detailed understanding of stem cells and how they mediate tumor pathogenesis will be critical in developing more effective cancer therapies...
  5. pmc Cancer stem cells: controversial or just misunderstood?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cell Stem Cell 4:203-5. 2009
    ..In this commentary, underlying points of contention are described with the aim of defining focal points for discussion and future consideration...
  6. ncbi request reprint Mechanisms controlling pathogenesis and survival of leukemic stem cells
    Craig T Jordan
    Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
    Oncogene 23:7178-87. 2004
    ..In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells...
  7. ncbi request reprint Searching for leukemia stem cells--not yet the end of the road?
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer Cell 10:253-4. 2006
    ..Biological features of leukemia stem cells in this system challenge previous thinking in several ways and suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia...
  8. pmc The leukemic stem cell
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 20:13-8. 2007
    ..This article summarizes recent findings in the leukemic stem cell field and discusses new directions for therapy...
  9. doi request reprint Targeting myeloid leukemia stem cells
    Craig T Jordan
    Departments of Medicine and Biomedical Genetics and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Sci Transl Med 2:31ps21. 2010
    ..Here the current understanding of the LSC phenotype is described, and the potential application of antibody-based treatment regimens is discussed...
  10. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009
    ..Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols...
  11. pmc Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
    Duane C Hassane
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
    Blood 111:5654-62. 2008
    ..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets...
  12. pmc Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
    ..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations...
  13. pmc An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4427-35. 2007
    ..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo...
  14. ncbi request reprint Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology
    Craig T Jordan
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Nat Clin Pract Oncol 2:224-5. 2005
  15. pmc The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells
    Yun Dai
    Division of Hematology Oncology, Department of Medicine, Virginia Commonwealth University, 401 College Street, Richmond, VA 23298, USA
    Br J Haematol 151:70-83. 2010
    ..They also raise the possibility that this strategy may target leukaemic progenitor cells...
  16. pmc The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
    Blood 105:4163-9. 2005
    ..On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy...
  17. ncbi request reprint The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
    ....
  18. ncbi request reprint Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells
    Sang Woo Kim
    Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA
    Blood 111:1644-53. 2008
    ..Together, these results indicate that PKK plays a pivotal role in the survival of human DLBCL cells and represents a potential target for DLBCL therapy...
  19. pmc Leukemia stem cells in a genetically defined murine model of blast-crisis CML
    Sarah J Neering
    James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
    Blood 110:2578-85. 2007
    ..Taken together, the system provides a powerful means by which the in vivo behavior of LSCs versus HSCs can be characterized and candidate treatment regimens can be optimized for maximal specificity toward primitive leukemia cells...
  20. doi request reprint A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors
    Christopher R Silvers
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Prostate 70:1379-87. 2010
    ..In order to help circumvent this challenge, we sought to develop an in vitro assay of human prostate cancer initiation employing a prostate-associated mesenchymal feeder layer...
  21. pmc In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells
    Benjamin J Frisch
    Endocrine Division, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 114:4054-63. 2009
    ..These novel effects of PGE(2) could be exploited clinically to increase donor ST-HSCs, which are highly proliferative and could accelerate hematopoietic recovery after stem cell transplantation...
  22. pmc The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene
    Pin Yi Wang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY, USA
    Blood 112:4184-92. 2008
    ....
  23. pmc High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells
    Faith M Young
    Department of Medicine, University of Rochester, Rochester, New York, USA
    Biol Blood Marrow Transplant 14:622-30. 2008
    ..Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias...
  24. ncbi request reprint Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells
    Jonathan M Weber
    Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester, NY 14642, USA
    Bone 39:485-93. 2006
    ....
  25. doi request reprint Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Cancer Cell 15:252-4. 2009
    ..In the current issue of Cancer Cell, a study by Santaguida et al. provides new insights into JunB's function and the genesis of myeloid disease...
  26. ncbi request reprint Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias
    Shimei Gong
    Department of Pediatrics, University of Kentucky, Lexington, KY 40536, USA
    Exp Hematol 30:1162-9. 2002
    ..We sought to identify OCT genes preferentially expressed in hematopoietic cells...
  27. ncbi request reprint Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice
    Meredith A Bostrom
    Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 27:600-6. 2007
    ..However, there is no direct evidence that this enzyme promotes atherogenic processes in vivo...
  28. ncbi request reprint Feverfew: weeding out the root of leukaemia
    Monica L Guzman
    Expert Opin Biol Ther 5:1147-52. 2005
    ..Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed...
  29. pmc Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels
    Ivan Topisirovic
    Institute for Research in Immunovirology and Cancer, University of Montreal, Montreal, Quebec H3T 1J4, Canada
    Mol Cell Biol 25:1100-12. 2005
    ....
  30. ncbi request reprint A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy
    Craig T Jordan
    Leuk Res 28:1121-2. 2004
  31. pmc Preferential induction of apoptosis for primary human leukemic stem cells
    Monica L Guzman
    Blood and Marrow Transplant Program, Markey Cancer Center, Division of HematologyOncology, University of Kentucky Medical Center, Lexington, KY 40536 0093 USA
    Proc Natl Acad Sci U S A 99:16220-5. 2002
    ..Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy...
  32. ncbi request reprint Considerations for targeting malignant stem cells in leukemia
    Monica L Guzman
    Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA
    Cancer Control 11:97-104. 2004
    ..Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease...
  33. pmc Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency
    Felicia D Goodrum
    Department of Molecular Biology, Princeton University, Princeton, NJ 80544, USA
    Proc Natl Acad Sci U S A 99:16255-60. 2002
    ..Some of these expressed viral genes may function in latency and are targets for further analysis. Altered gene expression in hematopoietic progenitors may be indicative of the nature and outcome of HCMV infection...
  34. pmc Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis
    Ivan Topisirovic
    Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York University, One Gustave Levy Place, New York, NY 10029, USA
    Mol Cell Biol 23:8992-9002. 2003
    ..Thus, our findings indicate that this nuclear function of eIF4E can contribute to leukemogenesis by promoting growth and by impeding differentiation...
  35. ncbi request reprint Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations
    Felicia Goodrum
    Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
    Blood 104:687-95. 2004
    ....
  36. doi request reprint The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 111:4681-9. 2008
    ..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease...

Research Grants9

  1. Cellular and Molecular Studies of Leukemic Stem Cellss
    Craig Jordan; Fiscal Year: 2006
    ..Collectively, these efforts will advance our understanding of basic mechanisms that underlie leukemic transformation and will improve strategies for the preferential ablation of LSCs. ..
  2. Selective in vivo Ablation of Leukemia Stem Cells
    Craig Jordan; Fiscal Year: 2007
    ..Collectively, the proposed studies will provide a detailed evaluation of how therapeutic agents impact the growth and survival of LSC in vivo. ..
  3. Amnis ImageStream Flow Cytometer
    Craig Jordan; Fiscal Year: 2007
    ..Taken together, the unique capabilities of the ImageStream system will therefore serve to strongly benefit a wide range of research activities. ..
  4. Selective in vivo Ablation of Leukemia Stem Cells
    Craig Jordan; Fiscal Year: 2009
    ..Collectively, the proposed studies will provide a detailed evaluation of how therapeutic agents impact the growth and survival of LSC in vivo. ..